



**CALGB ABSTRACTS @ The American Society of Hematology (ASH)
50th Annual Meeting and Exposition / December 6-9, 2008
Moscone Center / San Francisco, CA**

Date/Time/Location	Title/Author
Saturday, December 6, 2008 5:30 PM-7:30 PM Hall A (Moscone Center) Poster Session I-565	Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. <i>Lale Kostakoglu, MD, MPH, David J. Straus, MD, Heiko Schöder, MD, Ann S. LaCasce, MD, Nancy L Bartlett, MD, Nathan Hall, MD, PhD, Jeffrey L Johnson, PhD, Sin-Ho Jung, PhD, George P. Canellos, MD, Lawrence H Schwartz, MD, and Bruce D. Cheson, MD</i> [Abstract #1460]
Saturday, December 6, 2008 5:30 PM-7:30 PM Hall A (Moscone Center) Poster Session I-108	FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase II Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R] <i>Myron S. Czuczman, Jeffrey L. Johnson, Sin-Ho Jung, Bruce D. Cheson</i> [Abstract #1003]
Monday, December 8, 2008 7:45 AM 3001-3003-3005 West (Moscone Center) Oral Session	Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. <i>Kristie A. Blum, MD, Jeffrey L Johnson, Sin-Ho Jung, Bruce D. Cheson, MD and Nancy L. Bartlett, MD</i> [Abstract #232]
Monday, December 8, 2008 1:45 PM 3001-3003-3005 - West (Moscone Center) Oral Session	Biologic Prognostic Markers in Diffuse Large B-Cell Lymphoma Patients Treated with Dose Adjusted EPOCH-R: a CALGB 50103 Correlative Science Study. <i>Eric D Hsi, MD, Jonathan Said, Jeffrey L Johnson, Sin-Ho Jung, Raymond Lai, MD, Dan Jones, MD, PhD, Amy Chadburn, MD, Bruce D. Cheson, MD and Wyndham H. Wilson</i> [Abstract #476]